Market revenue in 2020 | USD 567.5 million |
Market revenue in 2028 | USD 924.1 million |
Growth rate | 6.3% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | CNS Cancer |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 49.27% in 2020. Horizon Databook has segmented the South Africa central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Neuropsychiatry disorders are the third biggest healthcare burden in the country, after HIV/AIDS and other infectious diseases. On the other hand, the prevalence of dementia is estimated to be ~8% with higher prevalence levels in the older age group (over 65 years).
As per the World Alzheimer’s report, approximately 187,000 individuals aged 65 & above are living with dementia in South Africa, and this number is predicted to rise to 250,000 by 2030, mainly due to a concurrent increase in older people in the region.
The most commonly prescribed drugs for Alzheimer’s in the region include donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl). South Africa aims to create future leaders in mental, neurological.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into South Africa central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account